DOI: https://doi.org/10.24959/nphj.14.1973

Sf-36 questionnaire as the instrument of the life quality assessment in patients with diabetes mellitus type 2

T. A. Germanyuk, T. I. Ivko

Abstract


Today diabetes mellitus (DM) significantly reduces the parameters of the life quality of patients. Therefore, the life quality assessment is current and promising direction of medicine, which allows to determine a reasonable method of treatment. The aim of this study was the use of SF-36 questionnaire for determining the quality of life of patients with T2DM when applying different schemes of pharmacotherapy. The research objectives are: 1) carrying out retrospective analysis of medical histories and treatment sheets of T2DM patients in hospital environment; 2) carrying out frequency analysis of the treatment regimens used; 3) analysis of patients included in the study; 4) carrying out the survey by a nonspecific SF-36 questionnaire; 5) determination of the quality of life in T2DM patients. The research object is the quality of life in T2DM patients in hospital environment. The research methods were retrospective, frequency analysis, life quality assessment by a nonspecific SF-36 questionnaire. The pharmacoeconomic research included 2 groups of patients: the first group (25 patients) received the combination of metformin+gliclazide (43.1% of cases), the second one (56 patients) received the combination of metformin + glimepiride (16%). Patients did not significantly differ from all of the parameters analyzed, and it enabled to compare their quality of life. The life quality parameters were assessed by a nonspecific SF-36 questionnaire. When studying the life quality in patients with the metformin + gliclazide scheme the average physical health component was 24.64±0.63 and the average mental health component was 25.24±0.78; in patients with the metformin + glimepiride scheme the average physical health component was 23.89±1.1 and the average mental health component was 24.37±0.55. These results indicate that the quality of life in patients is fairly low and does not depend on the pharmacotherapeutic scheme used, obviously it is due to the severity of the T2DM course and the presence of complications. The quality of life in patients according to the physical and mental components has fairly low indicators irrespective of the pharmacotherapeutic scheme used.


Keywords


diabetes mellitus; quality of life; pharmacotherapy; SF-36 questionnaire

Full Text:

PDF

GOST Style Citations


1. Воробьев П.А., Авксентьева М.В., Борисенко О.В. и др. Клинико-экономический анализ. Изд. 3-е, доп. с приложениями. – М.: Ньюдиамед, 2008. – 778 с.

2. Наказ Міністерства охорони здоров’я України від 22.05.2009 №356 «Протокол надання медичної допомоги хворим на неускладнений цукровий діабет».

3. Новик А.А., Ионова Т.И. Руководство по исследованию качества жизни в медицине. – М.: ОЛМА медиагрупп, 2007. – 314 с.

4. Стаценко М.Е., Щербакова Т.Г., Осипова А.О. // Укр. мед. журн. – 2008. – №2 (64). – С. 61-65.

5. Ягудина Р.И., Куликов А.Ю., Аринина Е.Е. Фармакоэкономика сахарного диабета второго типа. – М.: OOO «Медицинское информационное агентство», 2011. – С. 63-66.

6. Barbieri M., Drummond M., Rutten F. et al. // Value Health. – 2010. – Vol. 13(8). – P. 1028-1037.

7. De Vries F.M., Denig P., Visser S.T. et al. // Value Health. – 2014. – Vol. 17(2). – P. 223-230.

8. Parker D., Bechinger-English, Jagger C. et al. // Age and Ageing. – 2006. – Vol. 35, №4. – P. 376-381.

9. Renee J.G.A. Pharmacoeconomics: From Theory to Practice (Drug Discovery Series) Roca Raton. – Fl. CRC Press, 2009. – P. 119-133.

10. Walley T., Haycox A., Boland A. Pharmacoeconomics. – Elsevier Science, 2004. – P. 122-123.

11. www.idf.org

12. www.rand.org/health/surveys_tools/mos/mos_core_36item.html

13. therapy.irkutsk.ru/doc/sf36a.pdf





Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Abbreviated key title: Vìsn. farm.

ISSN 2415-8844 (Online), ISSN 1562-7241 (Print)